Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SomnoMedSOMNF 46 EV-to-EBITDA is 16.38 as of Aug. 02, 2026, which is 50% below its 10-year median of 32.57. GuruFocus rates SOMNF with a GF Score™ of 46/100 and a GF Value™ of $0.45. The stock has 3 warning signs investors should review. Among 512 Medical Devices & Instruments companies, SomnoMed ranks worse than 55.47% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SomnoMed's enterprise value is $61.45 Mil.
SomnoMed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $3.75 Mil. Therefore, SomnoMed's EV-to-EBITDA for today is 16.38.
The historical rank and industry rank for SomnoMed's EV-to-EBITDA or its related term are showing as below:
SOMNF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.82 Med: 32.57 Max: 250.75
Current: 15.34
During the past 13 years, the highest EV-to-EBITDA of SomnoMed was 250.75. The lowest was -77.82. And the median was 32.57.
SOMNF's EV-to-EBITDA is ranked worse than 55.47% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.39
vs SOMNF: 15.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SomnoMed's share price for today is $0.4479.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SomnoMed's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SomnoMed's EV-to-EBITDA falls into.
SomnoMed's current Enterprise Value is $61.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $3.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (SOMNF) has a EV-to-EBITDA of 16.38 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SomnoMed. This is 50% below median its historical median of 32.57. According to the industry distribution chart, SomnoMed ranks #284 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is SomnoMed's EV-to-EBITDA too high?
SomnoMed's current EV-to-EBITDA of 16.38 is 50% below median its 10-year median of 32.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.39. SomnoMed's value of 16.38 is 13.8% above this industry median. Based on the distribution chart, SomnoMed ranks #284 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, SomnoMed has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #284 out of 512 companies for EV-to-EBITDA. This places SomnoMed in the lower half of its industry. The industry median EV-to-EBITDA is 14.39. SomnoMed's value of 16.38 is 13.8% above this benchmark. While the company's 10-year median is 32.57 vs. the industry median of 14.39, SomnoMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.39, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current EV-to-EBITDA of 16.38 is 13.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SomnoMed. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current EV-to-EBITDA is 16.38, which is 50% below median its own 10-year median of 32.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
SomnoMed (SOMNF) has a current EV-to-EBITDA of 16.38. The stock's GF Value™ is $0.45, compared to a current price of $0.45 — trading 0.5% below its estimated fair value. The current EV-to-EBITDA is 16.38, which is 50% below median its 10-year median of 32.57 and 13.8% above the Medical Devices & Instruments industry median of 14.39. SomnoMed's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SomnoMed (SOMNF), the current EV-to-EBITDA is 16.38 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (SOMNF) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be undervalued.
The current stock price of $0.45 is trading 0.5% below its estimated GF Value™ of $0.45.
Key valuation signals for SOMNF:
EV-to-EBITDA: 16.38 (50% below median its 10-year median of 32.57)
GF Value™: $0.45 vs. price of $0.45 (0.5% below fair value)
Industry Position: 13.8% above the Medical Devices & Instruments median (#284 of 512)
No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
46GF Score
Get the complete analysis for SOMNF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOMNF has been successfully added to your 
